⌘K

09:09:46·110d

SECFilingvia Quantisnow

Amendment: SEC Form SCHEDULE 13G/A filed by Janux Therapeutics Inc.

ByQuantisnow·Wall Street's wire, on your screen.

JANX· Janux Therapeutics Inc.

Health Care

Original source

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Companies

JANX
Janux Therapeutics Inc.
Health Care

Recent analyst ratings

Apr 20UpdateBarclays$14.00
Apr 15UpdateUBS$15.00
Nov 18UpdateWolfe Research-
Sep 17UpdateBarclays$47.00
Sep 10UpdateStifel$45.00
Sep 10UpdateTruist$100.00

Related

PR21h
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development
ANALYST8d
Janux Therapeutics downgraded by Barclays with a new price target
PR11d
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
ANALYST13d
Janux Therapeutics downgraded by UBS with a new price target
PR27d
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment
SEC60d
SEC Form S-8 filed by Janux Therapeutics Inc.
SEC60d
SEC Form 10-K filed by Janux Therapeutics Inc.
SEC60d
Janux Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits